The BR/BD 530 and BR/BD 530 XL is used for wet-cleaning of level floors. It can easily be adjusted to a particular cleaning task by setting the water flow rate and extraction of dirty water. An operating width of up to 460 mm or 530 mm (XL model) and an 40 l fresh-water tank and dirty-water tank enable effective cleaning over a prolonged period. Sign this book or i will send my secret police after you, have them beat you until blood squirts out of your ears.
Item 7.01 Regulation FD Disclosure Trovagene, Inc. Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as 'anticipate,' 'believe,' 'forecast,' 'estimated' and 'intend' or other similar terms or expressions that concern Trovagene's expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.
While the list of factors presented in the 10-K is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Trovagene does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.
PCM-075: A PLK1 Inhibitor PCM-075 is an oral, highly-selective polo-like kinase 1 (PLK1) inhibitor Licensed exclusive global development and commercialization rights from Nerviano Medical Sciences, S.r.l. Polo-Like Kinase PLK1, PLK2, PLK3 are members of a family of serine/threonine kinases that are important regulators of cell-cycle progression15 PLK1 is a master regulator of mitotic progression and is the only family member expressed exclusively in dividing cells15 PLK1 regulates multiple steps of cell division15 Entry into mitosis Centrosome maturation Assembly of kinetochores and mitotic spindle Cytokinesis and exit of mitosis Role in genome stability during DNA replication 1. Takai N, et al. Oncogene 2005;24:28791; 2. Rudolph D, et al.
Clin Cancer Res 20102; 3. Chopra P, et al. Expert Opin Investig Drugs 2010;10:2743; 4. Strebhardt K. Nat Rev Drug Discov 2010;964360; 5. Zitouni S, et al.
Nat Rev Mol Cell Biol 2014;15:43352; 6. Takaki T, et al. Curr Opin Cell Bio 2008;20:65060. AML Market Opportunity AML: aggressive hematologic malignancy Incidence: 20,000 new cases and 10,400 deaths annually in the U.S. Prognosis: 5 year survival rate is 25% Treatment options vary based on patient condition / age, but can include: Chemotherapy Radiation Stem cell transplant Genetic landscape includes: NPM1, genetic marker in leukemia, accounting for 30% of all AML patients Other significant markers such as FLT3, DNMT3A, NRAS, KIT and fusion markers National Cancer Institute SEER 2016.
PCM-075 Clinical Development Plan Active IND for PCM-075 with clinical and regulatory organization engaged Phase 1/2 study planned with first patient to be dosed in 2017 Dose-escalation with PCM-075 as single agent and then in combination with chemotherapy agents to assess patient response and explore use of correlative biomarkers to select patients most likely to respond Inclusion criteria: adults with previously untreated AML, ineligible for intensive therapy, and ECOG 0-2 Clinical Advisory Board Dr. Jorge Cortes, MD Anderson Cancer Center (Deputy Chair Leukemia) Dr. Sandra Silberman, Duke Dr. Filip Janku, MD Anderson Cancer Center Dr.
David Berz, Beverly Hills Cancer Center. Trovagene ctDNA PCM Technology Proprietary ctDNA technology allows us to uniquely measure, with high clinical sensitivity, circulating genetic fragments of cancer tumors Over 120 patents issued and 60 pending Only liquid biopsy company with ctDNA technology compatible in both urine and blood for predicting patient response to therapeutics Trovera® single gene assays: CLIA and clinically validated tests for lung, colorectal, pancreatic, melanoma, other cancer types, and histiocytic disorders ERTHOSTM Select multigene panel with 200 mutations for broad applications, under development. Thank you for more information, please email [email protected] GRAPHIC3g121821moi001.gifGRAPHICbegin 644 g121821moi001.gifM1TE&.#EA/@-O OM01A3'-C6S%I23)M5R=F8%56M6$)G2$-J3$1N4T=O5$1Y2T5Q549S6TIU5$IU6TMZ5DU7%!5E%^6T=W84MM8TI9U!^8VEJ;'-T=GQ?' U^@$Z&/5:+3%.'